SCHEMBL2023767

SCHEMBL2023767

Cc1ccc(S(=O)(=O)n2ccc3c(C#N)cccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 0.55
KDM4E B2RXH2 1/20 0.51
UBE2N P61088 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.44
ALDH3A1 P30838 1/20 0.44
HTT P42858 1/20 0.44
NOD1 Q9Y239 1/20 0.44
HSD11B1 P28845 1/20 0.44
NR3C1 P04150 1/20 0.43
PGR P06401 1/20 0.43
NR3C2 P08235 1/20 0.43
HTR1A P08908 3/20 0.43
DRD2 P14416 2/20 0.43
HTR1D P28221 2/20 0.43
HTR1B P28222 2/20 0.43
HTR1F P30939 2/20 0.43
HTR7 P34969 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4785680 0.87 HTR6 (0.62) HTR6MEN1KMT2AHTTHTR1A
SCHEMBL28658988 0.82 KDM4E (0.63) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL23147825 0.82 HTR6 (0.41) HTR6KDM4EUBE2NL3MBTL1MEN1
SCHEMBL29721788 0.82 HTR6 (0.41) HTR6KDM4EUBE2NL3MBTL1MEN1
SCHEMBL3684432 0.81 HTR6 (0.58) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL30285388 0.81 HTR6 (0.58) HTR6KDM4EUBE2NL3MBTL1POLB
SCHEMBL6753718 0.81 HTR6 (0.61) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL15564770 0.80 L3MBTL1 (0.52) HTR6L3MBTL1MEN1KMT2APOLB
SCHEMBL29875473 0.80 KDM4E (0.71) HTR6KDM4EUBE2NL3MBTL1MEN1
SCHEMBL1419196 0.80 KDM4E (0.71) HTR6KDM4EUBE2NL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025074096-A1 P97 (VCP) ATPASE INHIBITORS Turbine Simulated Cell Technologies Ltd (GB) 2025-04-10 WO disclosed
EP-2516439-B1 DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2014-01-22 EP disclosed
US-8530648-B2 Diaza-spiro[5.5]undecanes NOVARTIS AG (CH) 2013-09-10 US disclosed
US-8530648-B2 Diaza-spiro[5.5]undecanes NOVARTIS AG (CH) 2013-09-10 US disclosed
US-8530648-B2 Diaza-spiro[5.5]undecanes NOVARTIS AG (CH) 2013-09-10 US disclosed
EP-2516439-A1 DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS Novartis AG (CH) 2012-10-31 EP disclosed
US-20120264748-A1 DIAZA-SPIRO[5.5]UNDECANES NOVARTIS AG (CH) 2012-10-18 US disclosed
US-20120264748-A1 DIAZA-SPIRO[5.5]UNDECANES NOVARTIS AG (CH) 2012-10-18 US disclosed
US-20120264748-A1 DIAZA-SPIRO[5.5]UNDECANES NOVARTIS AG (CH) 2012-10-18 US disclosed
WO-2011076747-A1 DIAZA-SPIRO[5.5]UNDECANES AS OREXIN RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264748-A1 DIAZA-SPIRO[5.5]UNDECANES REN, PKD1, NR3C2 HTR6 1518/4885KDM4E 2621/4885UBE2N 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.